v3.26.1
SEGMENTS (Tables)
 3 Months Ended
Jun. 30, 2026
Variable Interest Entities [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT

The following table summarizes segment financial information by business segment for the three months ended and at June 30, 2026:

 

(in thousands) 

Beyond

Air

  

Beyond
Cancer

   NeuroNos   Total 
Capital expenditures  $206   $-   $2   $208 
                     
Revenues  $1,768   $-   $-   $1,768 
Cost of revenues   1,543    -    -    1,543 
Research and development   1,747    54    158    1,959 
Selling, general, and administrative   3,663    189    1,026    4,878 
Loss from operations   (5,185)   (243)   (1,184)   (6,612)
Interest and finance expense   (1,492)   -    -    (1,492)
Other non-operating income/(expense)   (101)   41    10    (50)
Net loss before income taxes  $(6,778)  $(202)  $(1,174)  $(8,154)
Operating activities included in net loss:                    
Depreciation and amortization  $796   $1   $-   $797 
Stock-based compensation expense  $332   $66   $638   $1,036 
                     
Cash used in operations  $(4,355)  $(169)  $(422)  $(4,946)
Cash from investing   327    136    (2)   461 
Cash from financing   (170)   -    3,228    3,058 
Impact of exchange rates   (10)   (60)   49    (21)
Net change for the period  $(4,208)  $(93)  $2,853   $(1,448)

 

The following table summarizes segment financial information by business segment for the three months ended and at June 30, 2025:

 

(in thousands) 

Beyond

Air

  

Beyond
Cancer

   NeuroNos   Total 
Capital expenditures  $198   $-   $-   $198 
                     
Revenues  $1,760   $-   $-   $1,760 
Cost of revenues   1,604    -    -    1,604 
Research and development   2,234    529    323    3,086 
Selling, general, and administrative   3,328    952    407    4,687 
Loss from operations   (5,406)   (1,481)   (730)   (7,617)
Interest and finance expense   (548)   -    -    (548)
Other non-operating income/(expense)   110    (25)   2    87 
Net loss before income taxes  $(5,844)  $(1,506)  $(728)  $(8,078)
Operating activities included in net loss:                    
Depreciation and amortization  $795   $10   $-   $805 
Stock-based compensation expense  $1,000   $512   $65   $1,577 
                     
Cash used in operations  $(3,755)  $(439)  $(332)  $(4,526)
Cash from investing   215    361    -    576 
Cash from financing   4,066    -    -    4,066 
Impact of exchange rates   148    31    (52)   127 
Net change for the period  $674   $(47)  $(384)  $243 

 

The following table summarizes financial information by business segment at June 30, 2026:

 

(in thousands) 

Beyond

Air

   Beyond
Cancer		   NeuroNos   Total 
Cash, cash equivalents and marketable securities  $5,688   $813   $3,311   $9,812 
All other assets   23,310    (273)   42    23,079 
Total assets  $28,998   $540   $3,353   $32,891 
Total liabilities   (29,097)   (292)   (663)   (30,052)
Net assets  $(99)  $248   $2,690   $2,839 
Non-controlling interest  $-   $35   $807   $842 

 

The following table summarizes financial information by business segment at March 31, 2026:

 

(in thousands) 

Beyond

Air

   Beyond
Cancer		   NeuroNos   Total 
Cash, cash equivalents and marketable securities  $10,140   $1,043   $458   $11,641 
All other assets   23,901    (219)   62    23,744 
Total assets  $34,041   $824   $520   $35,385 
Total liabilities   (28,224)   (378)   (573)   (29,175)
Net assets  $5,817   $446   $(53)  $6,210 
Non-controlling interest  $-   $64   $20   $84